- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00504959
Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration
March 2, 2016 updated by: Novartis
A Phase IV, Long-term, Open-label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)
This extension study will investigate the long-term safety and tolerability of multiple intravitreal injections of ranibizumab administered to patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration who have been previously treated in either of the two ongoing ranibizumab studies CRFB002A2302 (EXCITE) or CRFB002A2303 (SUSTAIN
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
234
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Melbourne, Australia
- Novartis Investigational site
-
-
-
-
-
Laeken, Belgium
- Novartis Investigative Site
-
Leuven, Belgium
- Novartis Investigative Site
-
Liege, Belgium
- Novartis Investigative Site
-
-
-
-
-
Berlin, Germany
- Novartis Investigative Site
-
Bonn, Germany
- Novartis Investigative Site
-
Bremen, Germany
- Novartis Investigative Site
-
Chemnitz, Germany
- Novartis Investigative Site
-
Duesseldorf, Germany
- Novartis Investigative Site
-
Kiel, Germany
- Novartis Investigative Site
-
Koeln, Germany
- Novartis Investigative Site
-
Leipzig, Germany
- Novartis Investigative Site
-
Marburg, Germany
- Novartis Investigative Site
-
Muenchen, Germany
- Novartis Investigative Site
-
Siegburg, Germany
- Novartis Investigative Site
-
Tubingen, Germany
- Novartis Investigative Site
-
Wuerzburg, Germany
- Novartis Investigative Site
-
-
-
-
-
Budapest, Hungary
- Novartis Investigative Site
-
Debrecen, Hungary
- Novartis Investigative Site
-
-
-
-
-
Petach-Tikva, Israel
- Novartis Investigative Site
-
Tel - Hashomer, Israel
- Novartis Investigative Site
-
Tel-Aviv, Israel
- Novartis Investigative Site
-
-
-
-
-
Amsterdam, Netherlands
- Novartis Investigative Site
-
Nijmegen, Netherlands
- Novartis Investigative Site
-
-
-
-
-
Coimbra, Portugal
- Novartis Investigative Site
-
Porto, Portugal
- Novartis Investigative Site
-
-
-
-
-
Alicante, Spain
- Novartis Investigative Site
-
Barcelona, Spain
- Novartis Investigative Site
-
Madrid, Spain
- Novartis Investigative Site
-
Santiago de Compostela, Spain
- Novartis Investigative Site
-
Valencia, Spain
- Novartis Investigative Site
-
-
-
-
-
Ankara, Turkey
- Novartis Investigative Site
-
-
-
-
-
Bristol, United Kingdom
- Novartis Investigative Site
-
Southampton, United Kingdom
- Novartis Investigative Site
-
West Midlands, United Kingdom
- Novartis Investigative Site
-
Wolverhampton, United Kingdom
- Novartis Investigative Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Completion of 12-month treatment period of study CRFB002A2302 (EXCITE) or CRFB002A2303
Exclusion Criteria:
- Concurrent participation in another clinical trial, i.e. use of other investigational drugs
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 1
ranibizumab
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Safety assessed by incidence and severity of treatment emergent ocular and non-ocular adverse events over 24 month study period with ranibizumab monthly prn (0.5mg/0.05ml)
|
Secondary Outcome Measures
Outcome Measure |
---|
Efficacy assessed by mean change in BCVA from Baseline at M 6, 12, 18, and 24. Number of injections with ranibizumab. Safety assessed by AEs and SAEs leading to premature discont. of study drug, vital signs, and ophthalmic exams.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Novartis, Board of Hacettepe University , Ankara, turkey
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2007
Primary Completion (ACTUAL)
January 1, 2010
Study Completion (ACTUAL)
January 1, 2010
Study Registration Dates
First Submitted
July 19, 2007
First Submitted That Met QC Criteria
July 19, 2007
First Posted (ESTIMATE)
July 20, 2007
Study Record Updates
Last Update Posted (ESTIMATE)
March 4, 2016
Last Update Submitted That Met QC Criteria
March 2, 2016
Last Verified
March 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms
- Eye Diseases
- Retinal Degeneration
- Retinal Diseases
- Uveal Diseases
- Neoplastic Processes
- Choroid Diseases
- Metaplasia
- Macular Degeneration
- Neoplasm Metastasis
- Choroidal Neovascularization
- Neovascularization, Pathologic
- Physiological Effects of Drugs
- Antineoplastic Agents
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Ranibizumab
Other Study ID Numbers
- CRFB002A2402
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Subfoveal Choroidal Neovascularization (CNV)
-
Novartis PharmaceuticalsCompletedSubfoveal Choroidal Neovascularization CNV Secondary to Wet Age-related Macular Degeneration AMDAustralia
-
NovartisCompletedSubfoveal Choroidal Neovascularization(CNV) Secondary to Age-related Macular Degeneration (AMD)Japan
-
Asociación para Evitar la Ceguera en MéxicoCentro Medico IssemymUnknownSubfoveal Choroidal NeovascularizationMexico
-
Novartis PharmaceuticalsCompletedChoroidal Neovascularization (CNV)Korea, Republic of, Germany, Russian Federation, Turkey, Australia, Hungary, Switzerland, Italy, Lithuania, Denmark, Peru, Spain, Portugal, Canada, France, Latvia, Greece, Slovakia, Czech Republic, Poland, Singapore
-
Instituto Universitario de Oftalmobiología Aplicada...CompletedChoroidal Subfoveal/Juxtafoveal Neovascularization in High MyopiaSpain
-
AllerganTerminatedAge-Related Maculopathy | Subfoveal Choroidal NeovascularizationUnited States
-
PfizerTerminatedMacular Degeneration | Age Related Macular Degeneration (AMD) | Choroidal Neovascularization (CNV)Canada, Belgium, United Kingdom, France, Poland, Spain, Turkey, Czech Republic, Italy, Greece, Germany, Austria, Portugal, Denmark, Finland
-
RXi Pharmaceuticals, Corp.UnknownAge-related Macular Degeneration | Subfoveal Choroidal Neovascularization | Subretinal Scarring | Subretinal FibrosisUnited States
-
PfizerTerminatedAge-related Macular Degeneration (AMD) | Choroidal Neovascularization (CNV) | Early MarkersItaly, Portugal, United Kingdom
-
Novartis PharmaceuticalsCompletedVisual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM)China, India, Thailand, Hong Kong, Korea, Republic of, Philippines
Clinical Trials on ranibizumab
-
University of Campania "Luigi Vanvitelli"Completed
-
Hanscom, Thomas, M.D.Genentech, Inc.CompletedCentral Retinal Vein Occlusion | Macular Edema | Branch Retinal Vein OcclusionUnited States
-
University of Illinois at ChicagoGenentech, Inc.WithdrawnGlaucoma | Neovascular Glaucoma | New Onset Glaucoma | New Onset Neovascular Glaucoma
-
Especialistas en Retina Medica y Quirurgica Grupo...Centro de Retina Medica y Quirurgica S.C.CompletedDiabetic Macular EdemaArgentina, Mexico
-
Lupin Ltd.RecruitingNeovascular Age-related Macular DegenerationIndia
-
Hawaii Pacific HealthGenentech, Inc.CompletedPolypoidal Choroidal Vasculopathy | PCVUnited States
-
New England Retina AssociatesGenentech, Inc.CompletedChoroidal MelanomaUnited States
-
Samsung Bioepis Co., Ltd.CompletedAge-Related Macular DegenerationKorea, Republic of, United States, India, Germany, Hungary, United Kingdom, Czechia, Poland, Russian Federation
-
Peter A Campochiaro, MDGenentech, Inc.CompletedRetinal Vein OcclusionUnited States
-
Instituto de Olhos de GoianiaCompleted